1. Adoption of coronary artery disease - Reporting and Data System (CAD-RADS™) and observed impact on medical therapy and systolic blood pressure control.
- Author
-
Hull RA, Berger JM, Boster JM, Williams MU, Sharp AJ, Fentanes E, Maroules CD, Cury RC, and Thomas DM
- Subjects
- Aspirin administration & dosage, Biomarkers blood, Clinical Decision-Making, Coronary Artery Disease epidemiology, Coronary Stenosis epidemiology, Decision Support Systems, Clinical standards, Decision Support Techniques, Drug Utilization standards, Dyslipidemias blood, Dyslipidemias diagnosis, Dyslipidemias drug therapy, Dyslipidemias epidemiology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Hypertension diagnosis, Hypertension epidemiology, Hypertension physiopathology, Lipids blood, Medication Therapy Management standards, Platelet Aggregation Inhibitors administration & dosage, Practice Patterns, Physicians' standards, Predictive Value of Tests, Retrospective Studies, Risk Factors, Severity of Illness Index, Specialization, Antihypertensive Agents administration & dosage, Blood Pressure drug effects, Computed Tomography Angiography standards, Coronary Angiography standards, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease drug therapy, Coronary Stenosis diagnostic imaging, Coronary Stenosis drug therapy, Hypertension drug therapy, Multidetector Computed Tomography standards, Primary Prevention standards
- Abstract
Background: CAD-RADS was developed to standardize communication of per-patient maximal stenosis on coronary CT angiography (CCTA) and provide treatment recommendations and may impact primary prevention care and resource utilization. The authors sought to evaluate CAD-RADS adoption on preventive medical therapy and risk factor control amongst a mixed provider population., Methods: Statins, aspirin (ASA), systolic blood pressure and, when available, lipid panel changes were abstracted for 1796 total patients undergoing CCTA in the 12 months before (non-standard reporting, NSR, cohort) and after adoption of the CAD-RADS reporting template. Only initiation of a medication in a treatment naïve patient, escalation from baseline dose, or transition to a higher potency was considered an escalation/initiation in lipid therapy., Results: The CAD-RADS reporting template was utilized in 83.7% (751/897) of CCTAs after the CAD-RADS adoption period. After adjusting for any coronary artery disease (CAD) on CCTA, statin initiation/escalation was more commonly observed in the CAD-RADS cohort (aOR 1.46; 95%CI 1.12-1.90, p = 0.005), driven by higher rates of new statin initiation (aOR 1.79; 95%CI 1.23-2.58, p = 0.002). This resulted in a higher observed rates of total cholesterol improvement in the CAD-RADS cohort (58% vs 49%, p = 0.016). New ASA initiation was similar between reporting templates after adjustment for CAD on CCTA (aOR 1.40; 95%CI 0.97-2.02, p = 0.069). The ordering provider's specialty (cardiology vs non-cardiology) did not significantly impact the observed differences in initiation/escalation of statins and ASA (pinteraction = NS)., Conclusions: Adoption of CAD-RADS reporting was associated with increased utilization of preventive medications, regardless of ordering provider specialty., (Copyright © 2020 Society of Cardiovascular Computed Tomography. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF